ACO2 and prostate carcinoma: This metabolic profile aligns with a role of SLC39A1-KO in mitochondrial function, possibly through zinc-dependent inhibition of mitochondrial aconitase, as previously reported for prostate cancer cells (Singh et al, 2006).